Conclusions
cholangiocarcinoma
CHOLANGIOCARCINOMA
The encouraging antitumor activity and favorable safety profile support the use of pemigatinib as a treatment in previously treated Chinese patients with cholangiocarcinoma and 
Guo‐Ming Shi, Xiao‐Yong Huang, Tian‐Fu Wen, Tian‐Qiang Song and Ming Kuang contributed equally to this work.